Top News in Autoimmunity – Week of Feb. 20, 2019

Lupus Strongly Linked to Imbalances in Gut Microbiome

Scientists at the NYU School of Medicine have discovered that systemic lupus erythematosus (SLE) is strongly linked to imbalances in the body’s gut microbiome.

The study showed that 61 women diagnosed with lupus had five times more Ruminococcus gnavus gut bacteria compared to 17 women who were healthy and did not have lupus. The study also showed that the abnormal levels of gut bacteria appeared to positively correlate with lupus ‘flares’, which are instances when lupus symptoms, such as joint pain, skin rashes, and kidney dysfuntion, increase dramatically.

Dr. Gregg Silverman, immunologist and one of the lead researchers in the study, commented, “Our study strongly suggests that in some patients bacterial imbalances may be driving lupus and its associated disease flares.”

Dr. Silverman also stated that the study may give way to new treatments for the disease, such as probiotics, fecal transplants, or dietary regimens that prevent the growth of the Ruminococcus gnavus gut bacteria. The study also discusses the role of ‘leaky gut’ in triggering the body’s autoimmune reaction.

To read more about the study, click here.

Immunology ‘Boot Camp’ Emphasizes the Role of Chronic Stress in Autoimmune Disease

Leonard Calabrese, Vice Chairman of rheumatic and immunologic disease at the Cleveland Clinic, emphasized the role of chronic stress in the development of autoimmune diseases during an immunology ‘boot camp’.

During his speech, Calabrese cited data that chronic stress compromised the body’s surveillance of pathogens. As a result, modern stressors, such as PTSD, major depression, and the stress associated with being a caregiver, which are chronic in nature, may trigger the pathogenesis of autoimmune disease. This is in contrast to acute stress, which comes in response to immediate dangers, ‘like our ancestors encountering a saber-toothed tiger’, states Calabrese.

The link between chronic stress and autoimmunity has given way to the development a several new therapies. For example, parasympathetic and vagal nerve stimulation are now in development to treat pain-related and autoimmune conditions, such as Rheumatoid Arthritis (RA) and fibromyalgia.

To read more about this research, click here.

Interested in reading more? See last week’s top news in autoimmunity here.

Top News in Autoimmunity – Week of Dec. 19, 2018

NMO

Edmonton fighter diagnosed with rare disease

Victor Valimaki, a 37-year old professional fighter from Edmonton, Alberta, Canada, was left crippled by a rare autoimmune disorder.

Although Valimaki has fought in over two dozen professional fights, leading him to a successful career as an Ultimate Fighting Championship (UFC) mixed-martial arts fighter, he was recently diagnosed with neuromyelitis optica (NMO), otherwise known as Devic’s disease.

This autoimmune condition affects the body’s optic nerves, spinal cord and brain. For Valimaki, the disease caused him to lose his vision, speech, and ability to walk. Although he has since regained his sight, he is still struggling with the other consequences of the disorder.

Read his full story and watch the video on CTV News Edmonton.

Italian biotech company raises 17M€ to fund gene therapies for autoimmune diseases

An Italian biotechnology company named Altheia raised over 17 million euros this week to fund gene therapies that could potentially treat many incurable autoimmune diseases.

The company’s technology, which uses gene therapy to engineer bone marrow stem cells to express a molecule called PD-L1 that inactivates the immune system’s T cells. In other words, the molecule released will ‘hit the breaks’ on the body’s immune system, avoiding an immune system attack on healthy tissue.

Paolo Rizzardi, the company’s CEO, has stated that he expects clinical trials for autoimmune conditions such as multiple sclerosis and type 1 diabetes to begin in 2021.

Read more about this exciting new development on LABIOTECH.eu.